Abstract. Phencyclidine (PCP; 2.5 or 5.0 mg/kg) potentiated the effects of rewarding hypothalamic brain stimulation, causing parallel leftward shifts of the functions that relate rate of responding to stimulation frequency. Thus, like a number of other drugs of abuse, PCP lowered the "dose" of stimulation required to maintain responding at a given criterion. No progressive changes in the rewardpotentiating effects of PCP were evident when the rats were tested once per week for 8 weeks; there was neither tolerance nor sensitization to the initial rewarding properties of PCP. However, in subsequent locomotor tests rats appeared to be already sensitized to PCP; this raises the possibility that the electrical stimulation of the lateral hypothalamus itself maximally sensitized the animals to the stimulant effects of the drug.
Phencyclidine (PCP) is a complex drug with multiple actions in the brain: it is a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors (Anis et al. 1983) , it interferes with the reuptake of dopamine (Gerhardt et al. 1987) , and it interacts with sigma receptors (Mendelsohn et al. 1985; Walker et al. 1990 ). PCP affects a number of neurotransmitter systems (Johnson and Jones 1990) and can elicit disparate behavioral effects. For example, the drug appears to possess both reinforcing and aversive properties. The reinforcing properties of PCP are most evident in higher animals: monkeys will learn to lever press for intravenous PCP (Balster and Woolverton 1980) , and the drug is used compulsively by humans despite the fact that they often report aversive subjective effects (Crider 1986; Fram and Stone 1986) . In rodents, however, the reinforcing properties of intraCorrespondence to: R.A. Wise venous PCP appear to be substantially weaker than those of opiates and stimulants (Collins et al. 1984) . Furthermore, although some rats learn to self-administer PCP, their responding tends to be unreliable, and priming injections are often needed to initiate responding at the beginning of a test session; rats that respond reliably under cocaine or heroin reinforcement often do not continue to respond when switched to PCP reinforcement (P. Leone and R.A. Wise, unpublished observations) . In addition, rats tend to avoid rather than approach environments associated with the administration of PCP (Barr et al. 1985; Iwamoto 1986 ). Since rodents appear to be as sensitive to the aversive properties of PCP as they are to its reinforcing properties, a paradigm sensitive to only the rewarding effects of the drug would be useful for evaluating its habit-forming characteristics.
Most drugs that are rewarding in their own right facilitate intracranial self-stimulation (ICSS) in rodents (Wise 1980) , and it is thought that they do so by increasing the rewarding impact of the brain stimulation. Indeed, PCP effectively lowers the threshold for brain stimulation reward (Kornetsky and Esposito 1979 ) and increases the rate at which animals will lever press at fixed stimulation parameters (Schaeffer and Michael t990). Inasmuch as the rewarding effects of PCP and brain stimulation appear to augment one another, while the aversive properties of the drug remain constant regardless of whether an animal is receiving brain stimulation reward, it seems that the ICSS paradigm is largely insensitive to the sideeffects of PCP that are problematic in direct reward paradigms. In addition, the magnitude of the reward-potentiating effects of PCP can be precisely quantified using a variant of this task (Gallistel and Freyd 1987) ; thus, it can be determined whether the reward-relevant effects of PCP undergo tolerance with repeated administration, as is generally thought to accompany addiction, or sensitization, as is seen with the locomotor stimulant effects of the drug (Nabeshima et al. 1987) , and is thought to accompany the rewarding actions of drugs such as amphetamine, cocaine, and morphine (Lett 1989; Horger et al. 1990; Piazza et al. 1990 ).
Experiment 1
The purpose of experiment 1 was to quantify the rewardpotentiating effects of PCP, and to determine if these effects undergo progressive changes with repeated treatment. The effects of the drug on brain stimulation reward (BSR) were characterized using the "curve-shift" method, which is essentially a dose-response analysis of the rewarding effects of the stimulation (Liebman 1983) . With this method, rate of responding is determined across a working range of stimulation frequencies; the resultant rate-frequency function usually resembles a typical drug dose-response curve. Each animal is tested with stimulation frequencies high enough to sustain maximal responding, at low frequencies that fail to sustain responding, and at moderate intensities that sustain intermediate levels of responding. Drugs that are rewarding in their own right, such as amphetamine (Gallistel and Karras 1984) , morphine (Rompr6 and Wise 1989) , and nicotine (Bauco et al. 1991) typically cause parallel leftward shifts of such rate-frequency functions, suggesting synergism between the drug and the rewarding stimulation.
In order to determine if the reward-facilitating effects of PCP undergo tolerance or sensitization with repeated treatment, each animal was tested eight times in the BSR paradigm with the same dose of the drug. Since it has been reported that sensitization to the locomotor-stimulant effects of amphetamine is greatest after intermittent administration of the drug (Robinson and Becker 1986) , testing was performed at 1-week intervals.
Materials and methods
Animals and surgery. Twenty-four adult (350-400 g) male LongEvans rats were used; they were individually housed with free access to food and water and were maintained on a 12-h light (0800-2000 hours) 12-h dark cycle. Each animal was anesthetized with 65 mg/ kg (IP) sodium pentobarbital, and implanted with bilateral, monopolar, 254 ~tm stainless steel electrodes that were insulated with varnish except at their blunt tips. The electrodes were aimed at the lateral hypothalamic level of the medial forebrain bundle, 0.8 mm posterior to bregma, 1.8 mm lateral to the midline, and 8.0 mm below dura; the incisor bar was elevated to 5 mm above the intraaural line. A stainless steel wire wrapped around two of four stainless steel screws threaded into the skull served as the current return, and the entire assembly was imbedded in acrylic dental cement.
Self-stimulation training. At least 10 days after surgery, animals were trained to lever press for brain stimulation (0.5-s trains of rectangular cathodal pulses) in a 26 x 26 cm cage equipped with a single lever. Initially, the left electrode was used, and the stimulation frequency was held constant at 106 Hz while the current was adjusted to the lowest intensity that would sustain reliable responding (at least 40 lever-presses per minute). Once an appropriate current was found, it was held constant for the remainder of the experiment.
Once the animals had learned to lever-press at constant stimulation parameters, they were then adapted to brief tests with each of a descending series of 18 stimulation frequencies. Using the stimulation current previously determined to sustain reliable responding, each series of frequencies started at 106 Hz, and comprised discrete 1-min test trials for each frequency; a trial comprised an initial 5-s "priming" phase during which non-contingent stimulation was given, a 50-s test phase during which the number of lever-presses was recorded, and a 5-s period during which no stimulation was available. After each trial, the stimulation frequency was lowered by approximately 10% (0.05 log units), and another 1-min trial was started. After responding had been evaluated over the series of 18 frequencies, the procedure was repeated.
To determine the threshold frequency for brain stimulation reward (the lowest frequency at which the stimulation is found to be rewarding) for each rate-frequency function or "curve", a leastsquares line of best fit was plotted across the frequencies that sustained responding at 20, 30, 40, 50 and 60% of the maximum rate; threshold was defined as the frequency at which the line intersected the x-axis (Miliaressis et al. 1986; Romprb and Wise 1989 ).
Each animal was tested for 90 rain per day (five 18-min curves); drug testing started when the mean self-stimulation thresholds varied by less than 10% across 3 consecutive days of training. Because of motor artifacts or unstable responding when the left stimulating electrode was used, nine animals were retrained using the right electrode, which proved to be more reliable and was used for drug testing.
Drug testing. Thre e rate-frequency curves were determined for each animal before each drug test; the first determination was presumed to be unreliable and was not used for subsequent analysis. When there were less than 10% differences between thresholds for the second and third pre-injection curves, eight animals were assigned to each of three treatments: vehicle (physiological saline), or 2.5 or 5.0 mg/kg PCP (National Institute on Drug Abuse; doses expressed as salts). Immediately after intraperitoneal administration of the appropriate dosage, the animal was replaced in the test cage and five more rate-fl'equency curves were determined.
Each animal was tested 8 times, at weekly intervals. On the day prior to each drug test, the animals were given three rate-frequency determinations. On the following day, three curves were again determined, and if there was less than a 10% difference between the thresholds for the second and third curves, the animal was administered the same treatment as in the previous drug tests; if responding was not stable on the scheduled testing day, three pre-injection thresholds were determined on consecutive days until stability was re-established. The animals were given 5 days without stimulation between each set of tests.
One week following the eighth drug test, each animal was injected with saline under otherwise identical testing conditions. Histology. Following experiment 2 (see below), each of the 24 rats used in the BSR phase was anesthetized with an intraperitoneal injection of chloral hydrate (400 mg/kg), and was sacrificed by decapitation. The brain of each animal was frozen and sliced in 40-pm sections to confirm electrode placement.
Statistical analysis. Using the data from the second and third pre-injection rate-frequency function for each animal, the mean threshold and maximal response rate were determined; these values were considered to represent baseline response parameters. Treatment-induced changes in pre-injection threshold and maximal response rates were evaluated using separate analyses of variance (ANOVAs) with repeated measures. In the event of significant main effects or interactions, post hoc comparisons were made using Tukey's t-tests.
Results
The initial administration of PCP caused parallel leftward shifts in the rate-frequency functions. Lower levels of stimulation sustained pre-injection levels of responding after administration of either 2.5 (Fig. tA) or 5.0 mg/ kg PCP (Fig. 1B) . The threshold-lowering effects of PCP [F(2,21)=7.11, P<0.0t] were strongest during the first hour after administration ( Fig. 2A) : stimulation thresholds for animals treated with PCP were significantly lower than those of vehicle-treated animals through the third rate-frequency function (P <0.05). There were no statistically significant differences between the mean (Fig. 2B ). There was a significant Treatment x Time interaction [F(8,84) = 2.53, P < 0.05]; during the second rate frequency determination (19-36 •in) , the maximal response rates of animals administered 5.0 mg/ kg PCP were significantly diminished (P < 0.01).
The threshold-lowering effects of PCP did not change with repeated intermittent administration of the drug (Fig. 3A) . Since the strongest effects of PCP on stimulation threshold were during the first hour after administration, comparisons across days were made on the basis of the first three rate frequency functions in each of the eight test sessions. The animals were tested with PCP or saline vehicle once every 7-8 days (mean ___ SEM = 7.51 _+0.04); thresholds for animals repeatedly treated with 2.5 or 5.0 mg/kg PCP were consistently lower than those of animals treated with vehicle [F(2,21)=20.35, P<0.000t], but there were no progressive changes in the threshold across stimulation days.
Even with repeated treatment, the maximal response rates for animals treated with 5.0 mg/kg PCP were generally lower than those for animals treated with 2.5 mg/kg [F(2,21)=5.03, P<0.05]. However, there were no progressive changes in maximal response rates for any group of animals after repeated treatment (Fig. 3B) .
During the ninth test session, saline alone had no effect on threshold or asymptote, regardless of previous treatment (data not shown). 
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Discussion
PCP caused parallel leftward shifts of the rate-frequency functions, indicating that the drug enhanced the rewarding impact of MFB stimulation. Like amphetamine (Gallistel and Karras 1984), nicotine (Bauco et al. 1991) , and morphine (Rompr~ and Wise 1989), PCP caused significant decreases in the stimulation "dose" that was required to maintain normal levels of responding (see also Kornetsky and Esposito 1979) . Since it was synergistic with the rewarding impact of the stimulation, it would appear that it was a rewarding effect of PCP that accounted for the leftward shifts of the rate-frequency functions.
The magnitude of the PCP-induced threshold shift was relatively minor in comparison to shifts elicited by other drugs of abuse. A distinct advantage of the curveshift paradigm is that it measures shifts in stimulation threshold on a ratio scale (Gallistel and Freyd 1987) , allowing direct quantitative comparisons of threshold shifts between different drugs. Averaged over the first 60 rain after administration, 5.0 mg/kg PCP decreased stimulation thresholds by approximately 0.1 log units. Nicotine can cause a leftward shift of 0.2 log units (Bauco et al. 1991 ) and d-amphetamine can cause a parallel leftward shift of 0.3 log units (Gallistel and Karras 1984; Colle and Wise 1988) . The fact that PCP did not cause shifts as large as those caused by amphetamine and nicotine does not mean that it is inherently less rewarding than these drugs. Higher doses of PCP may further potentiate BSR; however, larger decreases in threshold might not be revealed using the curve-shift paradigm due to side effects of the drug. PCP (5.0 mg/kg) caused transient ataxia and circling that resulted in 10-15% decreases in maximal response rate during the second rate-frequency determination. Higher doses caused more substantial disruptions in performance; in a pilot experiment, 10.0 mg/kg PCP decreased lever-pressing rates to below 20% of pre-injection levels, making threshold determinations during the first hour of testing unreliable (data not presented).
Most drugs that potentiate the rewarding effects of brain stimulation (Wise 1980) , including PCP, have also been found to elevate extracellular levels of dopamine (DA) in microdialysis experiments (DiChiara and Imperato 1988; Carboni et al. 1989) . It is thought that PCP can increase synaptic DA through inhibition of dopamine reuptake (Gerhardt et al. 1987; Hernandez et al. 1988) and by increasing the firing rate of ventral tegmental area (VTA) neurons (Freeman and Bunney 1984) . Another agent that blocks the NMDA-associated ion channel, MK-801, has similar effects on the firing rate of VTA cells (French and Ceci 1990) . Interestingly, MK-801 causes a leftward shift in the BSR rate-frequency function similar to that of PCP (approximately 0.1 log units : Corbett 1989) , despite having little affinity for the dopamine uptake protein (Reid et al. 1990 ). Thus, the qualitative and quantitative similarities between the effects of PCP and MK-801 (Corbett 1989 ) support the notion that blockade of NMDA receptor function might be sufficient to potentiate the rewarding impact of brain stimulation. The mechanism of such an effect might involve disruption of complex feedback systems that normally inhibit VTA dopaminergic cells (Carlsson 1988; Imperato et al. 1990 ).
There was no evidence of progressive sensitization or tolerance to the reward-facilitating effects of repeated PCP over the course of the eight weekly test sessions. This finding is consistent with earlier findings involving repeated administration of some other habit-forming drugs. Esposito and Kornetsky (1977) and Kelley and Reid (1977) each found that administration of morphine decreased self-stimulation thresholds, but that the magnitude of this effect did not change after daily administration of morphine for up to 34 days. Similarly, it has been reported that the threshold-lowering effects of cocaine (Frank et al. t988 ) and nicotine (Bauco et al. 1991) are not altered with repeated administration. On the other hand, repeated administration of d-amphetamine has been reported by some (Predy and Kokkinidis 1984) but not other (Wise and Munn t993) investigators to elicit progressively greater increases in ICSS rates at several stimulation intensities.
Tolerance to PCP-induced ataxia has been reported in a study where a high dose (10.0 mg/kg) was given daily for 2 weeks (Nabeshima et al. 1987) . However, in the present experiment, where the drug was given once a week, there were no progressive changes in the performance-debilitating properties of 5.0 mg/kg PCP. It is conceivable that the lack of observable changes in the reward-potentiating characteristics of PCP in response to weekly injections were due to the testing of an inadequate dose; this issue was addressed in experiment 2.
Experiment 2
Intermittent administration causes progressive increases in the locomotor-stimulating properties of amphetamine and opiates (for review, see Robinson and Becker 1986; Kalivas and Stewart 1991) . The locomotor-stimulating properties of PCP have also been shown to undergo progressive sensitization, but with daily administration of a high dose (10 mg/kg) of the drug (Nabeshima et al. 1987) . To determine if the doses of PCP that were used in experiment 1 were sufficient to cause long-lasting behavioral changes, the locomotor-stimulating effects of repeated injections of 5.0 mg/kg PCP were assessed in a group of naive animals and in the animals from experiment 1.
Materials and methods
Animals. The 24 animals from experiment 1 and 16 previously untreated animals were used. The new animals were of similar weight and were handled for 10 days before use.
Apparatus. Locomotion was quantified in activity chambers (20.5 x 40.5 x 24.5 cm), which were constructed of wood (rear and two side walls), a wire screen ceiling, a floor with stainless steel rods spaced 1 crn apart, and a horizontally hinged plexiglas front door. Red light beams and photocells divided the length of the box into three sections. A white-noise generator (75 dB) masked extraneous sounds during testing.
Procedure. One week after completing the brain stimulation phase of the experiment, the locomotor-stimulating properties of PCP were evaluated. Each animal that had received brain stimulation was administered 5.0 mg/kg PCP (IP), and was immediately placed in an activity chamber; photocell counts were taken and stored at 5-min intervals. To determine if experience with brain stimulation had any effect on baseline levels of locomotor activity or sensitivity to the locomotor-stimulating properties of PCP, eight of the previously untreated animals (designated as naive) were injected with 5.0 mg/kg PCP, while the remaining eight animals received vehicle. The animals were tested for 2 h in darkness during their light cycle. This procedure was repeated every third day until the animals had been tested in the locomotor apparatus a total of eight times.
Results
Treatment with 5.0 mg/kg PCP had different effects on locomotor activity depending on the animals' previous (Fig. 4) . There was a significant treatment by session interaction [/7(28,245) = 4.07, P < 0.001]; on the first day of locomotor activity testing animals that had previously received the combination of brain stimulation and either 2.5 or 5.0 mg/kg PCP had higher levels of locomotor activity than animals that had previously received brain stimulation and vehicle (P < 0.05) or than either group of previously untreated animals (P<0.01). However, the animals that had received brain stimulation and vehicle were also more active than either group of previously untreated animals (P < 0.01). The locomotor scores of naive animals receiving PCP for the first time were not significantly different from those of previously untreated animals that received only vehicle.
With repeated treatment, naive animals became sensitized to the locomotor-stimulating effects of PCP: their activity scores were significantly greater during the eighth session than during the first session (P < 0.01). The locomotor scores of previously untreated animals administered vehicle waned significantly during the course of the experiment (P< 0.05). Similarly, activity scores for animals that had been previously treated with stimulation and 2.5 or 5.0 mg/kg PCP were significantly lower during the last day of treatment than during the first activity session (P <0.0I). The activity scores of animals previously treated with stimulation and vehicle did not change after repeated treatment with 5.0 mg/kg PCP.
Discussion
Although once-weekly administration of PCP did not alter its reward-facilitating effects in experiment l, it appears that this dosing regimen was adequate to cause long-lasting changes in psychomotor activation. Rats that had received either 2.5 or 5.0 mg/kg PCP in the brain stimulation phase of the experiment were subsequently more sensitive to the locomotor-stimulating properties of the drug than were animals receiving the drug for the first time. However, it is difficult to attribute this increase in sensitivity to the mere administration of PCP, since the control animals that had received brain stimulation with vehicle rather than PCP also had locomotor scores that were significantly greater than those of the two groups of previously untreated animals. On the first day of locomotor testing, the animals that had received brain stimulation and vehicle were substantially more active than the naive animals, although each group was receiving PCP for the first time and each displayed signs of ataxia. This finding implies that the previous electrical stimulation of the MFB itself had caused increases in sensitivity to the locomotor-stimulating properties of PCP. In fact, all rats that had received brain stimulation, including those that had received only vehicle over the 8 weeks of BSR testing, were as active during the first locomotor test as they were during subsequent tests. Thus, whereas naive animals were most active after the seventh administration of PCP, all animals that had received brain stimulation were maximally sensitized to the locomotor-stimulating effects of the drug before or during the initial activity test.
It has been proposed that the neuronal substrates subserving locomotion and reward are homologous (Schneirla 1959; Glickman and Schiff 1967; Wise and Bozarth 1987) ; if this were true, then one would expect treatments that sensitize animals to the locomotor-stimulating actions of habit-forming drugs would also sensitize them to the rewarding actions. Indeed, there is some evidence that supports this prediction. Previous experience with amphetamine (Piazza et al. 1990) or cocaine (Horger et al. 1990 ) appears to accelerate the acquisition of intravenous self-administration of these agents, and previous experience with amphetamine or morphine appears to enhance the establishment of drug-conditioned place preferences (Lett 1989) . Repeated testing with amphetamine appears to enhance the reward-potentiating action of this agent in one version of the brain stimulation reward paradigm (Predy and Kokkinidis 1984) but not in the curve-shift paradigm (Wise and Munn 1993) . Inasmuch as the reward-enhancing effects of drugs in the BSR paradigm are thought to reflect a summation of drug reward and brain stimulation reward (Wise et al. 1992) , it is thus surprising that treatments that sensitized rats to the locomotor-stimulating effects of PCP failed to sensitize them to the reward-enhancing effects of this drug. This finding suggests either that the mechanisms by which this agent facilitates locomotion and BSR are at least partially independent, or that there is a previously under-appreciated degree of task-specificity in psychomotor stimulant sensitization.
